STUDIES ON PROTECTIVE EFFECTS OF A VACCINE, BASED ON RECOMBINANT Ag85, TB10 AND FliC PROTEINS

At present time, there is an obvious need for a new generation of vaccines as the most effective preventive approach, in order to stop spreading of tuberculosis infection. So far, the most popular strategy is aimed at heterological vaccination. The idea is to use BCG, or improved BCG, or attenuated...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	V. V. Yeremeev, I. V. Duhovlinov, A. I. Orlov, A. F. Malenko, E. A. Fedorova, M. B. Balazovsky, V. Ya. Gergert
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2017
Materias:	tuberculosis vaccine immunity recombinant antigens protection mycobacterium Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/9534a35afe534c619ea142582505b590
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9534a35afe534c619ea142582505b590
record_format	dspace
spelling	oai:doaj.org-article:9534a35afe534c619ea142582505b5902021-11-18T08:03:46ZSTUDIES ON PROTECTIVE EFFECTS OF A VACCINE, BASED ON RECOMBINANT Ag85, TB10 AND FliC PROTEINS1563-06252313-741X10.15789/1563-0625-2017-2-197-202https://doaj.org/article/9534a35afe534c619ea142582505b5902017-05-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/1223https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XAt present time, there is an obvious need for a new generation of vaccines as the most effective preventive approach, in order to stop spreading of tuberculosis infection. So far, the most popular strategy is aimed at heterological vaccination. The idea is to use BCG, or improved BCG, or attenuated M. tuberculosis for primary vaccination. For the further booster vaccination one may apply thw s.c. subunit or vector vaccines, containing protective mycobacterial proteins. The aim of our investigation was to evaluate protective effects of a new vaccine based on recombinant bacterial proteins Ag85, ТВ10 and FliC. We used a model with aerosol M. tuberculosis H37Rv infection, and compared lung and spleen CFU counts and life-span of vaccinated versus non-vaccinated С57BL/6 mice. As a result, we revealed three vaccine variants with comparable protective capacity against BCG using our experimental model. The most promising variant is suggested for testing in preclinical trials.V. V. YeremeevI. V. DuhovlinovA. I. OrlovA. F. MalenkoE. A. FedorovaM. B. BalazovskyV. Ya. GergertSPb RAACIarticletuberculosisvaccineimmunityrecombinant antigensprotectionmycobacteriumImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 19, Iss 2, Pp 197-202 (2017)
institution	DOAJ
collection	DOAJ
language	RU
topic	tuberculosis vaccine immunity recombinant antigens protection mycobacterium Immunologic diseases. Allergy RC581-607
spellingShingle	tuberculosis vaccine immunity recombinant antigens protection mycobacterium Immunologic diseases. Allergy RC581-607 V. V. Yeremeev I. V. Duhovlinov A. I. Orlov A. F. Malenko E. A. Fedorova M. B. Balazovsky V. Ya. Gergert STUDIES ON PROTECTIVE EFFECTS OF A VACCINE, BASED ON RECOMBINANT Ag85, TB10 AND FliC PROTEINS
description	At present time, there is an obvious need for a new generation of vaccines as the most effective preventive approach, in order to stop spreading of tuberculosis infection. So far, the most popular strategy is aimed at heterological vaccination. The idea is to use BCG, or improved BCG, or attenuated M. tuberculosis for primary vaccination. For the further booster vaccination one may apply thw s.c. subunit or vector vaccines, containing protective mycobacterial proteins. The aim of our investigation was to evaluate protective effects of a new vaccine based on recombinant bacterial proteins Ag85, ТВ10 and FliC. We used a model with aerosol M. tuberculosis H37Rv infection, and compared lung and spleen CFU counts and life-span of vaccinated versus non-vaccinated С57BL/6 mice. As a result, we revealed three vaccine variants with comparable protective capacity against BCG using our experimental model. The most promising variant is suggested for testing in preclinical trials.
format	article
author	V. V. Yeremeev I. V. Duhovlinov A. I. Orlov A. F. Malenko E. A. Fedorova M. B. Balazovsky V. Ya. Gergert
author_facet	V. V. Yeremeev I. V. Duhovlinov A. I. Orlov A. F. Malenko E. A. Fedorova M. B. Balazovsky V. Ya. Gergert
author_sort	V. V. Yeremeev
title	STUDIES ON PROTECTIVE EFFECTS OF A VACCINE, BASED ON RECOMBINANT Ag85, TB10 AND FliC PROTEINS
title_short	STUDIES ON PROTECTIVE EFFECTS OF A VACCINE, BASED ON RECOMBINANT Ag85, TB10 AND FliC PROTEINS
title_full	STUDIES ON PROTECTIVE EFFECTS OF A VACCINE, BASED ON RECOMBINANT Ag85, TB10 AND FliC PROTEINS
title_fullStr	STUDIES ON PROTECTIVE EFFECTS OF A VACCINE, BASED ON RECOMBINANT Ag85, TB10 AND FliC PROTEINS
title_full_unstemmed	STUDIES ON PROTECTIVE EFFECTS OF A VACCINE, BASED ON RECOMBINANT Ag85, TB10 AND FliC PROTEINS
title_sort	studies on protective effects of a vaccine, based on recombinant ag85, tb10 and flic proteins
publisher	SPb RAACI
publishDate	2017
url	https://doaj.org/article/9534a35afe534c619ea142582505b590
work_keys_str_mv	AT vvyeremeev studiesonprotectiveeffectsofavaccinebasedonrecombinantag85tb10andflicproteins AT ivduhovlinov studiesonprotectiveeffectsofavaccinebasedonrecombinantag85tb10andflicproteins AT aiorlov studiesonprotectiveeffectsofavaccinebasedonrecombinantag85tb10andflicproteins AT afmalenko studiesonprotectiveeffectsofavaccinebasedonrecombinantag85tb10andflicproteins AT eafedorova studiesonprotectiveeffectsofavaccinebasedonrecombinantag85tb10andflicproteins AT mbbalazovsky studiesonprotectiveeffectsofavaccinebasedonrecombinantag85tb10andflicproteins AT vyagergert studiesonprotectiveeffectsofavaccinebasedonrecombinantag85tb10andflicproteins
_version_	1718422367053545472

STUDIES ON PROTECTIVE EFFECTS OF A VACCINE, BASED ON RECOMBINANT Ag85, TB10 AND FliC PROTEINS

Ejemplares similares